Disc Medicine (NASDAQ:IRON) Now Covered by Analysts at TD Cowen

Research analysts at TD Cowen assumed coverage on shares of Disc Medicine (NASDAQ:IRON) in a research note issued to investors on Thursday,Briefing.com Automated Import reports. The firm set a “buy” rating on the stock.

Several other equities analysts have also weighed in on IRON. Raymond James upgraded Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their price target for the company from $66.00 to $110.00 in a research note on Monday, November 4th. HC Wainwright restated a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a research report on Tuesday, January 21st. Scotiabank increased their target price on Disc Medicine from $70.00 to $73.00 and gave the company a “sector outperform” rating in a research report on Wednesday, January 22nd. Wedbush reissued an “outperform” rating and issued a $90.00 price target (up previously from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. Finally, Morgan Stanley upgraded shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective for the company in a research report on Tuesday, November 5th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $88.90.

Disc Medicine Stock Performance

Shares of NASDAQ IRON opened at $54.60 on Thursday. Disc Medicine has a 1 year low of $25.60 and a 1 year high of $77.60. The company’s fifty day moving average price is $58.42 and its 200 day moving average price is $55.44. The company has a market capitalization of $1.62 billion, a PE ratio of -13.72 and a beta of 0.73.

Insider Buying and Selling

In related news, insider Pamela Stephenson sold 3,137 shares of Disc Medicine stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $171,217.46. Following the transaction, the insider now owns 69,529 shares in the company, valued at approximately $3,794,892.82. This trade represents a 4.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Rahul Khara sold 7,500 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $62.75, for a total value of $470,625.00. Following the completion of the sale, the insider now owns 14,035 shares of the company’s stock, valued at approximately $880,696.25. The trade was a 34.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 76,037 shares of company stock worth $4,650,001. 4.24% of the stock is owned by insiders.

Hedge Funds Weigh In On Disc Medicine

A number of institutional investors have recently bought and sold shares of IRON. Sterling Capital Management LLC grew its stake in shares of Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after buying an additional 503 shares during the period. GF Fund Management CO. LTD. acquired a new position in Disc Medicine in the fourth quarter valued at approximately $40,000. Tower Research Capital LLC TRC grew its position in Disc Medicine by 47.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock worth $52,000 after acquiring an additional 266 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Disc Medicine by 45.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after acquiring an additional 337 shares during the last quarter. Finally, Quest Partners LLC purchased a new stake in Disc Medicine in the third quarter valued at $131,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.